AstraZeneca's COVID-19 Vaccine Potentially Triggers Response Against Brazil Variant: Reuters

Preliminary data from a study conducted at the University of Oxford suggests that AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine is effective against the P1 or Brazilian variant, reports Reuters.

  • The data indicate that the vaccine will not need modification to protect against the variant.
  • The study did not disclose the vaccine’s exact efficacy against the variant, but full results should be possibly released by March.
  • Early results from a small study showed that the AstraZeneca vaccine was less effective against the South African variant, similar to P1.
  • Subsequently, South Africa paused the use of the vaccine in the country.
  • Reuters also reported that a small-sample lab study showed that Sinovac Biotech’s COVID-19 vaccine failed to generate a sufficient immune response.
  • According to a recent study, one dose of either Pfizer Inc (NYSE: PFE)/BioNtech SE (NASDAQ: BNTX) or Oxford-AstraZeneca’s COVID-19 vaccine is more than 80% effective in reducing infections and severe illness among those aged over 80.
  • Price Action: AZN shares are trading 0.73% higher at $47.59 in market trading hours on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!